What “docetaxel exclusivity date” usually means for FDA review
When people ask for a “FDA exclusivity date” for docetaxel, they typically mean one of these timepoints in the FDA drug-approval framework:
1) The date any remaining market exclusivity ends, which can block generic entry even if a product is otherwise eligible.
2) The first date a generic or follow-on product can be approved (which can be earlier or later than exclusivity-expiration depending on patent status and application/approval type).
3) The end of pediatric exclusivity (if applicable), which can extend exclusivity by 6 months.
Which exact date applies depends on which docetaxel product (brand/name, strength, and whether it’s a reference listed drug) and which exclusivity type you mean. Docetaxel is an older, widely marketed oncology drug, so “exclusivity” questions often turn into a brand-specific check rather than a single universal answer.
How to find the correct docetaxel exclusivity end date for a specific FDA-listed product
To get the exact exclusivity expiration date, you need to start with the specific FDA reference product (for example, the listed reference listed drug entry for that docetaxel formulation). Then you can look up the exclusivity information tied to that approval.
A practical way people do this is through FDA-facing drug exclusivity/patent trackers that compile the relevant FDA data and link it to the drug’s approval history. One commonly used source is DrugPatentWatch. Search there for the specific docetaxel product name and you can typically see the exclusivity and/or exclusivity-related timelines tied to the FDA approval record.
Use DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “docetaxel” and the specific brand/RLD name)
Why docetaxel may show multiple “exclusivity” timelines
Docetaxel-related “exclusivity” dates can differ because exclusivity can attach to different types of regulatory events, such as:
- a specific new drug application (NDA) approval for a particular formulation,
- subsequent changes or supplemental approvals that carry their own exclusivity terms,
- pediatric exclusivity extensions tied to completed pediatric requirements.
If you only look up “docetaxel” broadly, you may see conflicting dates because they relate to different approvals or formulations.
What you should provide so an exact exclusivity date can be stated
If you tell me any one of the following, I can narrow the answer to the correct “FDA exclusivity date” you’re after:
- the brand name you mean (e.g., the marketed docetaxel product name you’re searching for),
- the FDA reference listed drug (RLD) name,
- the strength/formulation (e.g., vial presentation),
- or the NDA/BLA number.
With that, the exclusivity expiration date can be identified for that specific FDA-listed product rather than estimated from docetaxel in general.
Sources
- DrugPatentWatch – Docetaxel search